Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

3SBio

DB:83B
Snowflake Description

Flawless balance sheet and good value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
83B
DB
HK$22B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

3SBio Inc. develops, manufactures, markets, and sells biopharmaceuticals. The last earnings update was 10 days ago. More info.


Add to Portfolio Compare Print
  • 3SBio has significant price volatility in the past 3 months.
83B Share Price and Events
7 Day Returns
12.9%
DB:83B
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-40%
DB:83B
-7.4%
DE Biotechs
-14.2%
DE Market
83B Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
3SBio (83B) 12.9% 17.3% -16.7% -40% -9.9% -
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • 83B underperformed the Biotechs industry which returned -7.4% over the past year.
  • 83B underperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
83B
Industry
5yr Volatility vs Market

Value

 Is 3SBio undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of 3SBio to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for 3SBio.

DB:83B Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 16 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.6%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:83B
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 6.3%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.05
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.048 (1 + (1- 25%) (14.25%))
1.107
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.11
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.107 * 6.33%)
6.62%

Discounted Cash Flow Calculation for DB:83B using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for 3SBio is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:83B DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (CNY, Millions) Source Present Value
Discounted (@ 6.62%)
2020 1,024.33 Analyst x8 960.73
2021 1,298.33 Analyst x8 1,142.13
2022 1,359.78 Analyst x6 1,121.93
2023 1,635.90 Analyst x3 1,265.96
2024 1,769.70 Analyst x3 1,284.48
2025 1,856.99 Est @ 4.93% 1,264.16
2026 1,918.94 Est @ 3.34% 1,225.23
2027 1,961.50 Est @ 2.22% 1,174.66
2028 1,989.66 Est @ 1.44% 1,117.55
2029 2,007.32 Est @ 0.89% 1,057.48
Present value of next 10 years cash flows CN¥11,614.00
DB:83B DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= CN¥2,007.32 × (1 + -0.39%) ÷ (6.62% – -0.39%)
CN¥28,527.60
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= CN¥28,527.60 ÷ (1 + 6.62%)10
CN¥15,028.65
DB:83B Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= CN¥11,614.00 + CN¥15,028.65
CN¥26,642.65
Equity Value per Share
(CNY)
= Total value / Shares Outstanding
= CN¥26,642.65 / 2,538.48
CN¥10.5
DB:83B Discount to Share Price
Calculation Result
Exchange Rate CNY/HKD
(Reporting currency to currency of SEHK:1530)
1.097
Value per Share
(HKD)
= Value per Share in CNY x Exchange Rate (CNY/HKD)
= CN¥10.5 x 1.097
HK$11.52
Non-primary Listing Adjustment Factor 1 share in DB:83B represents 0.12309x of SEHK:1530
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.12309x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (HKD) x Listing Adjustment Factor
= HK$ 11.52 x 0.12309
€1.42
Value per share (EUR) From above. €1.42
Current discount Discount to share price of €1.05
= -1 x (€1.05 - €1.42) / €1.42
25.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price 3SBio is available for.
Intrinsic value
26%
Share price is €1.05 vs Future cash flow value of €1.42
Current Discount Checks
For 3SBio to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • 3SBio's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • 3SBio's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for 3SBio's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are 3SBio's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:83B PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in CNY CN¥0.38
SEHK:1530 Share Price ** SEHK (2020-04-08) in HKD HK$8.53
SEHK:1530 Share Price converted to CNY reporting currency Exchange rate (HKD/ CNY) 0.911 CN¥7.77
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of 3SBio.

DB:83B PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SEHK:1530 Share Price ÷ EPS (both in CNY)

= 7.77 ÷ 0.38

20.24x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • 3SBio is good value based on earnings compared to the Europe Biotechs industry average.
  • 3SBio is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does 3SBio's expected growth come at a high price?
Raw Data
DB:83B PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 20.24x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 16 Analysts
21.4%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

DB:83B PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 20.24x ÷ 21.4%

0.95x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • 3SBio is good value based on expected growth next year.
Price based on value of assets
What value do investors place on 3SBio's assets?
Raw Data
DB:83B PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in CNY CN¥3.79
SEHK:1530 Share Price * SEHK (2020-04-08) in HKD HK$8.53
SEHK:1530 Share Price converted to CNY reporting currency Exchange rate (HKD/ CNY) 0.911 CN¥7.77
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:83B PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SEHK:1530 Share Price ÷ Book Value per Share (both in CNY)

= 7.77 ÷ 3.79

2.05x

* Primary Listing of 3SBio.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • 3SBio is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess 3SBio's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. 3SBio has a total score of 4/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is 3SBio expected to perform in the next 1 to 3 years based on estimates from 16 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
21.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is 3SBio expected to grow at an attractive rate?
  • 3SBio's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • 3SBio's earnings growth is expected to exceed the Germany market average.
  • 3SBio's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:83B Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:83B Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 16 Analysts 21.4%
DB:83B Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 16 Analysts 11.9%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:83B Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 16 Analyst Estimates (S&P Global) See Below
All numbers in CNY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:83B Future Estimates Data
Date (Data in CNY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 9,671 1,843 1
2023-12-31 8,966 1,697 1
2022-12-31 7,939 1,759 1,919 11
2021-12-31 7,084 1,920 1,719 16
2020-12-31 6,042 1,508 1,429 15
2020-04-09
DB:83B Past Financials Data
Date (Data in CNY Millions) Revenue Cash Flow Net Income *
2019-12-31 5,318 974
2019-09-30 5,185 1,029
2019-06-30 5,053 1,403 1,084
2019-03-31 4,818 1,277 1,181
2018-12-31 4,584 1,150 1,277
2018-09-30 4,393 1,160 1,167
2018-06-30 4,202 1,171 1,057
2018-03-31 3,968 1,122 996
2017-12-31 3,734 1,074 935
2017-09-30 3,467 1,017 877
2017-06-30 3,199 960 818
2017-03-31 2,998 982 766

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • 3SBio's earnings are expected to grow significantly at over 20% yearly.
  • 3SBio's revenue is expected to grow by 11.9% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:83B Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 16 Analyst Estimates (S&P Global) See Below

All data from 3SBio Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:83B Future Estimates Data
Date (Data in CNY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 0.74 0.88 0.54 8.00
2021-12-31 0.66 0.78 0.48 15.00
2020-12-31 0.55 0.63 0.43 13.00
2020-04-09
DB:83B Past Financials Data
Date (Data in CNY Millions) EPS *
2019-12-31 0.38
2019-09-30 0.41
2019-06-30 0.43
2019-03-31 0.46
2018-12-31 0.50
2018-09-30 0.46
2018-06-30 0.42
2018-03-31 0.39
2017-12-31 0.37
2017-09-30 0.35
2017-06-30 0.32
2017-03-31 0.30

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • 3SBio is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess 3SBio's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
3SBio has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has 3SBio performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare 3SBio's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • 3SBio has delivered over 20% year on year earnings growth in the past 5 years.
  • 3SBio's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • 3SBio's 1-year earnings growth is negative, it can't be compared to the Europe Biotechs industry average.
Earnings and Revenue History
3SBio's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from 3SBio Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:83B Past Revenue, Cash Flow and Net Income Data
Date (Data in CNY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 5,318.09 973.72 2,280.64 526.57
2019-09-30 5,185.46 1,028.99 2,235.46 263.28
2019-06-30 5,052.84 1,084.26 2,190.28
2019-03-31 4,818.35 1,180.72 2,099.10
2018-12-31 4,583.87 1,277.17 2,007.92
2018-09-30 4,392.72 1,166.99 1,911.19
2018-06-30 4,201.56 1,056.82 1,814.45
2018-03-31 3,967.95 996.11 1,731.13
2017-12-31 3,734.33 935.39 1,647.81
2017-09-30 3,466.75 876.93 1,601.23
2017-06-30 3,199.16 818.48 1,554.65
2017-03-31 2,998.22 765.52 1,436.54
2016-12-31 2,797.29 712.56 1,318.43
2016-09-30 2,492.48 641.60 1,103.73
2016-06-30 2,187.67 570.64 889.03
2016-03-31 1,930.40 548.46 799.68
2015-12-31 1,673.13 526.28 710.33
2015-09-30 1,502.59 455.99 676.01
2015-06-30 1,364.07 341.01 744.04
2015-03-31 1,247.46 316.37 673.12
2014-12-31 1,130.85 291.73 602.20
2014-09-30 1,043.76 237.84 580.73
2013-12-31 875.40 95.89 439.09
2013-09-30 841.77 94.59 431.89 -54.44

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • 3SBio has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • 3SBio used its assets less efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • 3SBio has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess 3SBio's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
3SBio has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is 3SBio's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up 3SBio's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • 3SBio is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • 3SBio's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of 3SBio's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from 3SBio Company Filings, last reported 3 months ago.

DB:83B Past Debt and Equity Data
Date (Data in CNY Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 10,359.32 2,801.99 2,555.01
2019-09-30 10,359.32 2,801.99 2,555.01
2019-06-30 9,553.64 3,678.96 2,329.99
2019-03-31 9,553.64 3,678.96 2,329.99
2018-12-31 8,907.37 3,365.36 1,860.74
2018-09-30 8,907.37 3,365.36 1,860.74
2018-06-30 8,100.27 3,870.90 2,608.28
2018-03-31 8,100.27 3,870.90 2,608.28
2017-12-31 7,629.65 4,473.43 3,103.19
2017-09-30 7,629.65 4,473.43 3,103.19
2017-06-30 7,117.75 2,478.35 523.74
2017-03-31 7,117.75 2,478.35 523.74
2016-12-31 6,766.34 3,168.75 1,039.77
2016-09-30 6,766.34 3,168.75 1,039.77
2016-06-30 6,140.54 3,544.78 926.26
2016-03-31 6,140.54 3,544.78 926.26
2015-12-31 5,635.47 405.00 1,900.47
2015-09-30 5,635.47 405.00 1,900.47
2015-06-30 5,189.61 672.36 4,193.58
2015-03-31 5,189.61 672.36 4,193.58
2014-12-31 943.59 617.43 163.66
2014-09-30 773.87 300.00 477.49
2013-12-31 1,081.80 0.00 527.86
2013-09-30
  • 3SBio's level of debt (27%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (62.4% vs 27% today).
  • Debt is well covered by operating cash flow (50.1%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 57.6x coverage).
X
Financial health checks
We assess 3SBio's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. 3SBio has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is 3SBio's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from 3SBio dividends. Estimated to be 0.07% next year.
If you bought €2,000 of 3SBio shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate 3SBio's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate 3SBio's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:83B Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 16 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:83B Future Dividends Estimate Data
Date (Data in CN¥) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 0.00 4.00
2021-12-31 0.01 8.00
2020-12-31 0.00 7.00
2020-04-09
DB:83B Past Annualized Dividends Data
Date (Data in CN¥) Dividend per share (annual) Avg. Yield (%)
2019-09-30 0.000 0.000
2019-08-21 0.000 0.000
2019-04-30 0.000 0.000
2019-03-20 0.000 0.000
2018-04-30 0.055 0.496
2018-03-26 0.055 0.379

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as 3SBio has not reported any payouts.
  • Unable to verify if 3SBio's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of 3SBio's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as 3SBio has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of 3SBio's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess 3SBio's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can 3SBio afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. 3SBio has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of 3SBio's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jing Lou
COMPENSATION CN¥6,450,000
AGE 56
CEO Bio

Dr. Jing Lou, M.D., Ph.D. is a Co-Founder of 3SBio Inc. and has been its Chairman of the Board since April 1, 2012 and also serves as the Chief Executive Officer and President. Dr. Lou served as the Chief Executive Officer of Shenyang Sunshine since 2000. He joined Shenyang Sunshine as Director of Research and Development in 1995. Prior to that, Dr. Lou founded Lifegen, Inc., a Maryland Corporation and an investee company of Shenyang Sunshine, to optimize the manufacturing processes for EPIAO and TPIAO in the U.S. Dr. Lou has been an Executive Director at 3SBio Inc. since September 2006. He served as a Director of Isotechnika Pharma Inc. from November 9, 2010 to July 29, 2011. Dr. Lou completed his post-doctoral study at the U.S. National Institutes of Health in 1995. He received his Ph.D. in Molecular and Cell Biology in 1993 from Fordham University, where he researched interferon signal transduction of gene regulation and received his medical doctor degree in 1985 from Shanghai 2nd Military Medical University.

CEO Compensation
  • Jing's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Jing's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the 3SBio management team in years:

4
Average Tenure
50.5
Average Age
  • The tenure for the 3SBio management team is about average.
Management Team

Jing Lou

TITLE
Co-Founder
COMPENSATION
CN¥6M
AGE
56

Dongmei Su

TITLE
Senior VP & Executive Director
COMPENSATION
CN¥2M
AGE
49

Dan Lou

TITLE
Co Founder and Advisor
COMPENSATION
CN¥710K
AGE
83
TENURE
8 yrs

Kevin Xiao

TITLE
Chief Operating Officer
AGE
50
TENURE
4.1 yrs

Zhenping Zhu

TITLE
President of Research & Development and Chief Scientific Officer
AGE
54
TENURE
3.3 yrs

Hui Dang

TITLE
Director of Risk and Compliance Management
AGE
47
TENURE
4 yrs

Tom Folinsbee

TITLE
Director of Corporate Development
AGE
51

Xin Ma

TITLE
Vice President of the Human Resources Department
AGE
58

Rachel You

TITLE
Director of the Finance Department & Financial Controller
AGE
40
TENURE
9.2 yrs

Junlin Wang

TITLE
President of Guojian
AGE
46
TENURE
4 yrs
Board of Directors Tenure

Average tenure and age of the 3SBio board of directors in years:

4.8
Average Tenure
50
Average Age
  • The tenure for the 3SBio board of directors is about average.
Board of Directors

Jing Lou

TITLE
Co-Founder
COMPENSATION
CN¥6M
AGE
56
TENURE
8 yrs

Dongmei Su

TITLE
Senior VP & Executive Director
COMPENSATION
CN¥2M
AGE
49
TENURE
7.8 yrs

Robert Pu

TITLE
Independent Non-Executive Director
COMPENSATION
CN¥263K
AGE
50
TENURE
4.8 yrs

Lap Yan Wong

TITLE
Independent Non-Executive Director
AGE
48
TENURE
0.5 yrs

Bin Huang

TITLE
Non-Executive Director
COMPENSATION
CN¥1M
AGE
58
TENURE
5.4 yrs

David Parkinson

TITLE
Independent Non-Executive Director
COMPENSATION
CN¥263K
AGE
69
TENURE
4.8 yrs

Ke Tang

TITLE
Non-Executive Director
AGE
39
TENURE
0.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
06. Apr 20 Sell JPMorgan Chase & Co, Brokerage and Securities Investments Company 01. Apr 20 01. Apr 20 -8,790,295 €0.96 €-8,477,478
06. Apr 20 Buy JPMorgan Chase & Co, Brokerage and Securities Investments Company 01. Apr 20 01. Apr 20 1,419,916 €0.96 €1,369,386
06. Apr 20 Sell JPMorgan Chase & Co, Private Banking and Investment Banking Investments Company 01. Apr 20 01. Apr 20 -191,500 €0.96 €-184,685
03. Apr 20 Buy JPMorgan Chase & Co, Brokerage and Securities Investments Company 31. Mar 20 31. Mar 20 84,323,405 €0.96 €80,618,052
06. Mar 20 Sell JPMorgan Chase & Co, Brokerage and Securities Investments Company 03. Mar 20 03. Mar 20 -3,733,905 €1.00 €-3,726,066
03. Mar 20 Buy JPMorgan Chase & Co, Brokerage and Securities Investments Company 27. Feb 20 27. Feb 20 3,361,164 €1.05 €3,514,094
26. Feb 20 Sell JPMorgan Chase & Co, Brokerage and Securities Investments Company 21. Feb 20 21. Feb 20 -1,110,017 €1.21 €-1,346,944
03. Jan 20 Sell JPMorgan Chase & Co, Brokerage and Securities Investments Company 30. Dec 19 30. Dec 19 -750,509 €1.15 €-859,655
03. Jan 20 Buy JPMorgan Chase & Co, Private Banking and Investment Banking Investments Company 30. Dec 19 30. Dec 19 30,000 €1.15 €34,363
02. Jan 20 Buy JPMorgan Chase & Co, Brokerage and Securities Investments Company 27. Dec 19 27. Dec 19 2,703,003 €1.10 €2,976,671
20. Dec 19 Sell JPMorgan Chase & Co, Brokerage and Securities Investments Company 17. Dec 19 17. Dec 19 -13,659,612 €1.24 €-16,888,251
08. Nov 19 Buy JPMorgan Chase & Co, Private Banking and Investment Banking Investments Company 05. Nov 19 05. Nov 19 13,296,393 €1.69 €22,420,422
30. Sep 19 Sell The Sun Shine Trust Company 26. Sep 19 26. Sep 19 -2,500,000 €1.49 €-3,728,864
15. May 19 Sell JPMorgan Chase & Co, Brokerage and Securities Investments Company 10. May 19 10. May 19 -10,280,380 €1.60 €-16,417,907
13. May 19 Buy JPMorgan Chase & Co, Private Banking and Investment Banking Investments Company 08. May 19 08. May 19 5,014,751 €1.62 €8,108,948
08. May 19 Buy JPMorgan Chase & Co, Brokerage and Securities Investments Company 03. May 19 03. May 19 21,708,416 €1.66 €36,055,223
08. May 19 Sell JPMorgan Chase & Co, Private Banking and Investment Banking Investments Company 03. May 19 03. May 19 -25,105,008 €1.66 €-41,696,579
08. May 19 Buy JPMorgan Chase & Co, Private Banking and Investment Banking Investments Company 03. May 19 03. May 19 33,500 €1.66 €55,640
08. May 19 Sell J.P. Morgan Asset Management, Inc. Company 03. May 19 03. May 19 -108,000 €1.66 €-179,376
08. May 19 Buy J.P. Morgan Asset Management, Inc. Company 03. May 19 03. May 19 5,500 €1.66 €9,135
29. Apr 19 Buy JPMorgan Chase & Co, Private Banking and Investment Banking Investments Company 24. Apr 19 24. Apr 19 2,806,764 €1.70 €4,774,994
X
Management checks
We assess 3SBio's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. 3SBio has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

3SBio Inc. develops, manufactures, markets, and sells biopharmaceuticals. The company provides TPIAO, a recombinant human thrombopoietin for chemotherapy-induced thrombopenia and immune thrombocytopenia; Ruisiyi, a non-steroidal aromatase inhibitor for breast cancer; EPIAO and SEPO recombinant human erythropoietins to treat anemia; Wanwei, a 5-HT3 receptor antagonist antiemetic drug for vomiting; and Intefen, a recombinant human interferon to treat lymphatic or hematopoietic malignancies and viral infections. It also offers Inleusin, a recombinant human interleukin2 for the treatment of renal cell carcinoma, melanoma, and thoracic fluid build-up; Etanercept, a recombinant human type II tumor necrosis factor receptor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; BYETTA for the glycemic control in patients with type 2 diabetes; and SPARIN, an injectable low-molecular-weight heparin calcium for the treatment of prophylaxis and deep vein thrombosis, as well as for the prevention of clotting during hemodialysis. In addition, the company provides Mandi for the treatment of male-pattern alopecia and alopecia areata; Aiyishu to treat iron-deficiency anemia; Qiming Keli for retinopathy caused by type-2 diabetes; Disu, a bidirectional immunomodulator for the prevention and treatment of chronic bronchitis, cold, and asthma; Jiannipai, a recombinant humanized anti-CD25 monoclonal antibody injection to prevent acute rejection after renal transplantation; and Humulin, a recombinant insulin for diabetes. Further, the company engages in the contract development and manufacturing, trading, project management and consultation, and provision of technology services activities. It has collaboration agreements with Toray Industries, Inc.; Refuge Biotechnologies, Inc.; Samsung Bioepis Co., Ltd.; Verseau Therapeutics, Inc.; and Taiwan Liposome Company, Ltd. 3SBio Inc. was incorporated in 2006 and is headquartered in Shenyang, the People’s Republic of China.

Details
Name: 3SBio Inc.
83B
Exchange: DB
Founded: 2006
HK$2,568,622,253
2,538,480,632
Website: http://www.3sbio.com
Address: 3SBio Inc.
No. 3 A1, Road 10,
Shenyang Economy and Technology Development Zone,
Shenyang,
Liaoning Province, 110027,
China
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SEHK 1530 Ordinary Shares The Stock Exchange of Hong Kong Ltd. HK HKD 11. Jun 2015
OTCPK TRSB.F Ordinary Shares Pink Sheets LLC US USD 11. Jun 2015
DB 83B Ordinary Shares Deutsche Boerse AG DE EUR 11. Jun 2015
SHSC 1530 Ordinary Shares Stock Exchange of Hong Kong Limited - Shanghai - Hong Kong Stock Connect HK HKD 11. Jun 2015
SZSC 1530 Ordinary Shares The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect HK HKD 11. Jun 2015
Number of employees
Current staff
Staff numbers
5,404
3SBio employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/09 00:04
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/04/08
Last earnings filing: 2020/03/30
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.